Telomerase reverse transcriptase promoter mutations in bladder cancer: High frequency across stages, detection in urine, and lack of association with outcome

European Urology

Volumn 65, Issue 2, 2014, Pages 360-366

  Allory, Yves ^a,b   Beukers, Willemien ^c   Sagrera, Ana ^a   Flández, Marta ^a   Marqués, Miriam ^a   Márquez, Mirari ^a   Van Der Keur, Kirstin A ^c   Dyrskjot, Lars ^d   Lurkin, Irene ^c   Vermeij, Marcel ^c   Carrato, Alfredo ^e   Lloreta, Josep ^f,g   Lorente, José A ^f   Carrillo De Santa Pau, Enrique ^a   Masius, Roy G ^c   Kogevinas, Manolis ^f,h,i,j   Steyerberg, Ewout W ^c   Van Tilborg, Angela A G ^c   Abas, Cheno ^a,c   Orntoft, Torben F ^d   Zuiverloon, Tahlita C M ^c   Malats, Núria ^a   Zwarthoff, Ellen C ^c   Real, Francisco X ^a,g   more..

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g UNIVERSITAT POMPEU FABRA   (Spain)

^h Centre de Recerca Epidemiologica Ambiental (CREAL IMIM)   (Spain)

ⁱ CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^j NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

more..

Author keywords

Bladder cancer; Clinical end point; Somatic mutations; TERT gene; Urine based diagnosis

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE;

AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; ENZYME ASSAY; FEMALE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SNAPSHOT ASSAY; SOMATIC MUTATION; URINALYSIS; UROTHELIAL BLADDER CANCER;

BLADDER CANCER; CLINICAL END POINT; SOMATIC MUTATIONS; TERT GENE; URINE-BASED DIAGNOSIS;

AGED; CELL LINE, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; MUTATION; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NETHERLANDS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SPAIN; TELOMERASE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84891835829     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.08.052     Document Type: Article

References (19)

1. M.J. Resnick, J.C. Bassett, and P.E. Clark Management of superficial and muscle-invasive urothelial cancers of the bladder Curr Opin Oncol 25 2013 281 288
2. M. Babjuk, W. Oosterlinck, and R. Sylvester et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
3. A. Stenzl, N.C. Cowan, and M. De Santis et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2011 1009 1018
4. D. Cappellen, C. De Oliveira, and D. Ricol et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas Nat Genet 23 1999 18 20
5. C. Billerey, D. Chopin, and M.H. Aubriot-Lorton et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors Am J Pathol 158 2001 1955 1959
6. N.M. Luis, E. López-Knowles, and F.X. Real Molecular biology of bladder cancer Clin Transl Oncol 9 2007 5 12
7. L.C. Kompier, I. Lurkin, M.N. van der Aa, B.W. van Rhijn, T.H. van der Kwast, and E.C. Zwarthoff FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy PloS One 5 2010 e13821
8. J.M. Van Oers, I. Lurkin, and A.J. van Exsel et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine Clin Cancer Res 11 2005 7743 7748
9. T.C. Zuiverloon, M.N. van der Aa, and T.H. van der Kwast et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer Clin Cancer Res 16 2010 3011 3018
10. J.W. Shay, and W.E. Wright Role of telomeres and telomerase in cancer Semin Cancer Biol 21 2011 349 353
11. C. Günes, and K.L. Rudolph The role of telomeres in stem cells and cancer Cell 152 2013 390 393
12. F.W. Huang, E. Hodis, M.J. Xu, G.V. Kryukov, L. Chin, and L.A. Garraway Highly recurrent TERT promoter mutations in human melanoma Science 339 2013 957 959
13. S. Horn, A. Figl, and P.S. Rachakonda et al. TERT promoter mutations in familial and sporadic melanoma Science 339 2013 959 961
14. P.J. Killela, Z.J. Reitman, and Y. Jiao et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal Proc Natl Acad Sci U S A 110 2013 6021 6026
15. M. García-Closas, N. Malats, and D. Silverman et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses Lancet 366 2005 649 659
16. S. Hernández, E. López-Knowles, and J. Lloreta et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas J Clin Oncol 24 2006 3664 3671
17. M.A. Sanchini, R. Gunelli, and O. Nanni et al. Relevance of urine telomerase in the diagnosis of bladder cancer JAMA 294 2005 2052 2056
18. D. Tilki, M. Burger, and G. Dalbagni et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer Eur Urol 60 2011 484 492
19. D.E. Gomez, R.G. Armando, and D.F. Alonso AZT as a telomerase inhibitor Front Oncol 2 2012 113